

CURRICULUM VITAE

Steven Michael Opal
Associate Professor of Medicine
Director of the Infectious Disease Fellowship Program
Brown University School of Medicine
Providence, Rhode Island

PERSONAL INFORMATION

Date of Birth: 07/21/50

Place of Birth: Bainbridge, New York, USA

Citizenship: USA

Marital Status: Married, two children

Military Experience: 9 years, active duty US Army, honorable discharge 1985,
Army commendation medal

Social Security Number: 128-40-9307

Home Address: 11 Briarwood Drive
Barrington, Rhode Island 02806

Professional Address: Division of Infectious Diseases
The Memorial Hospital of Rhode Island
111 Brewster Street
Pawtucket, Rhode Island 02860

Business Telephone Number: (401) 729-2545

FAX Number: (401) 729-2795

E-Mail Address: Steven_Opal@brown.edu

EDUCATION

1972 B.S. Cornell University, B.S.in Microbiology with Distinction,
Dean's List

1976 M.D.

Albany Medical College of Union
University, Albany, New York.
Alpha Omega Alpha, Honor Medical
Society - Cum Laude, M.D.

POST GRADUATE TRAINING

Internship:
1976-77

Fitzsimons Army Medical Center,
Denver, Colorado

Residency:

1977-79

Internal Medicine Residency,
Fitzsimons Army Medical Center

1978-79

Chief Resident in Medicine
Fitzsimons Army Medical Center
Denver, Colorado

Fellowship:

1980-82

Infectious Disease Fellowship
Walter Reed Army Medical Center
Washington, D.C.

Tropical Medicine Training:

1981

Armed Forces Institute of Pathology Walter Reed Army
Institute of Research. Washington, D.C.

PROFESSIONAL LICENSES AND BOARD CERTIFICATION

1985

Rhode Island License Registration No. 6676; DEA No.
B00997518

1979

American Board of Internal Medicine

1984

American Board of Internal Medicine Infectious Disease
Specialty

1987

License for use of radioactive isotopes in Biomedical research;
RI # 7B-043-01

PROFESSIONAL FACULTY APPOINTMENTS

1980-82	Teaching Fellow, Uniformed Services University of the Health Sciences
1981-82	Instructor, Uniformed Services, University of the Health Sciences
1984-85	Clinical Assistant Professor of Medicine, University of Colorado Health Sciences Center, Denver, Colorado
1985-1991	Assistant Professor of Medicine, Brown University School of Medicine
1988-present	Adjunct Assistant Professor of Medicine, University of Rhode Island
1988-present	Associate, Brown University Program in Geographic Medicine
1991-present	Associate Professor of Medicine, Brown University School of Medicine
1995-present	Director of the Infectious Disease Fellowship Program, Brown University School of Medicine

HOSPITAL APPOINTMENTS

1982-83	Assistant Chief, Infectious Disease Service, Fitzsimons Army Medical Center, Aurora, Colorado Member, Pharmacy Committee and Infection Control Service
1984-85	Chief, Infectious Disease Service, Fitzsimons Army Medical Center, Aurora, Colorado Chairman, Infection Control Committee
1985-present	Director: Travel Clinic, and Infection Control Service, Memorial Hospital of Rhode Island, Pawtucket, Rhode Island.
1985-present	Active Medical Staff Attending Physician, Department of Medicine, Division of Infectious Disease, Memorial Hospital Pawtucket, Rhode Island
1986-present	Consulting Staff Attending Physician, Department of Medicine Miriam Hospital, Providence, RI.

1989-present Consulting Staff, Attending Physician. Rhode Island Hospital
Providence, Rhode Island

1995-present Active Staff physician, Infectious Disease Division, Roger Williams
Medical Center, Providence, RI.

HOSPITAL COMMITTEES

Chairperson; Infection Control Committee, Member; Pharmacy
Committee, Chairperson, Clinical Competence Committee, Intern
Selection Committee, Radiation Safety Committee

UNIVERSITY COMMITTEES

Member, Biohazard Safety Committee, Brown University
Curriculum Committee, Infectious Disease Fellowship Program,
Brown University
Knowledge Base Working Group on Health Promotion and Disease
Prevention
PHD Promotions Board - Microbiology and Immunology

HONORS

Clinical Teacher of The Year Award Fitzsimons Army Medical
Center 1983, 1984, 1985.

Teacher Of The Year Award Memorial Hospital Brown University
Affiliated Hospital - 1986, 1987, 1988, 1994.

Special Award in Excellence in Teaching: Brown University
Infectious Disease Fellows - 1990.

Master of Arts Degree (ad eundem) - Brown University, 1992

NATIONAL CONVENOR, RESEARCH AWARDS, AND HONORS

William Christian Annual Award for Excellence in Scientific
Research, American Federation of Clinical Research, Seattle,
Washington - 1991

Bright Young Investigator Award, International Immunocompromised
Host Society, Boulder Colorado, 1992.

Co-moderator, Mini-symposium on Immunomodulators - International Immunocompromised Host Society. Boulder, Colorado. June, 25, 1992.

Co-moderator, The Second Consensus Development Conference on the Treatment of Radiation Injury. (Sepsis Conference) . National Radiobiology Research Institute, Bethesda, Maryland, April 14-17, 1993.

Chairman, The Fourth Annual Vienna Shock Society Meeting. Experimental Hopes in the Treatment of Sepsis session . Vienna, Austria. May 8, 1993.

Co-moderator, Session on Endotoxin, sepsis and shock models, ICAAC Annual Meeting, New Orleans, LA. October 19, 1993

Co-moderator, Oral presentation of abstracts to the 5th International Steglitz Symposium on Sepsis, Berlin, Germany, February 10, 1994

Co-moderator and panel member. International Consensus Conference on Immunotherapy of Sepsis. 3rd International Congress on the Immune Consequences of Trauma, Shock and Sepsis. Munich, Germany. March 1994.

Co-moderator and panel member, Session on Inflammatory Mediators and Design of Clinical Sepsis Trials. Autumnal Thematic Meeting on Sepsis, Deauville, France, November 8, 1994

Co-moderator. Session on Experimental Studies in Endotoxin Research. ICAAC Annual Meeting, Orlando, Florida, October 5, 1994

Co-moderator, Session on Immunomodulators. 15th Annual International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, March 22, 1995.

Chairman - Session on Endotoxemia and Vaccine Development. National Consultants Meeting for Infectious Diseases. Palm Beach, Florida, May 20, 1995

Meet the Professor Session of the American College of Physicians Meeting - Rhode Island Chapter. April 25, 1995

Co-moderator, Session on Clinical Trials for Sepsis, ICAAC Annual meeting, San Francisco, CA, September 21, 1995

Moderator, Session on Experimental Studies on Endotoxin and Sepsis, ICAAC Annual meeting, San Francisco, CA, September 20, 1995.

Moderator, Session on multiresistent pathogens in the ICU - the 16th International Symposium on Intensive Care and Emergency Medicine, Brussels, Belgium, March 21, 1996.

Co-chairman - International Workshop on Antibiotic-Induced Endotoxin Release. Morristown, NJ, January 16, 1996.

Chairman - Clinical Trials for Septic Shock Workshop, IBC International Conference on Endotoxemia and Septic Shock, Boston, MA, June 24-26, 1996

Co-moderator - Session on sepsis. The 36th ICAAC Annual Meeting, New Orleans, LA, September 17, 1996

Chairman - Session on Antibiotic Use in the ICU. The 10th Annual Meeting of the Society of Anesthesia, Pulmonary, Intensive Care and Emergency Medicine. Trieste, Italy. November 6, 1996.

NATIONAL OR INTERNATIONAL REVIEW COMMITTEES:

- | | |
|------|---|
| 1993 | Board Member: VA Cooperative Studies Program Coordinating Center - Data Monitoring Board on Infectious Diseases - Hyperimmune globulin Studies in Prevention of Nosocomial Infection. |
| 1993 | Independent Review Panel: VA Research Program of Investigator-initiated Grant Proposals - Infectious Diseases and Shock Research. |
| 1995 | International Immunocompromised Host Society - Committee on Inflammatory Cells and Mediators. |

TEST PREPARATION COMMITTEES:

Infectious Disease Subspecialty Section; Medical Knowledge Self Assessment Program, American College of Physicians-1994

BOOK EDITOR:

- 1995 Textbook of Infectious Diseases and Microbiology: Section Editor: Commonly Encountered Problems. (S. Opal & J. Cohen,) Mosby-Wolfe Publishers, London, U.K. (Publication date - 1998)
- 1996 Endotoxin: Its Role in Health and Disease; Section editor on experimental models and clinical medicine (D. Morrison, S. Opal, H. Braude, S. Vogel editors). Marcel Dekker Publishers (Publication date - 1998).

MAJOR TEACHING ROLES

- Preceptor: Second, third, and fourth year medical students; Physical Diagnosis, Internal Medicine Clerkship, Infectious Diseases.
- Lecturer: Brown University Integrated Medical Sciences Course in Infectious Diseases (Assistant course leader - 1989, 1990, 1991)
Brown University American Contemporary Health Series
Brown University Graduate Immunology Series
Brown University Course UC 107, Health Problems of The Developing World.
Brown University Course - Bio128 - Basic Pharmacology
Brown University Course BIO158 - Microbiology and Basic Immunology
Brown University Course BIO160 - Advanced Immunology
Brown University Course BIO184 - Basic and Clinical Pathology
Brown University Course BIO254 - Immunology of Infectious Diseases
University of Rhode Island, Graduate Program in Clinical Laboratory Science.
Brown University AIDS Program For Primary Care Physicians

MEMBERSHIP AND FELLOWSHIP IN SOCIETIES

- 1983 Member, American Society for Microbiology
1985 Member, Infectious Disease Society of America
1987 Member, American Medical Association
1987 Member, Rhode Island Medical Society
1990 Member, American Federation of Clinical Research
1991 Member, Society for Critical Care Medicine
1992 Member, International Immunocompromised Host Society.
1993 Member, International Endotoxin Society
1995 Fellow, Infectious Disease Society of America

OTHER APPOINTMENTS

Advisor:

Hospital Association of Rhode Island Protocols in Infectious Diseases;
AIDS Advisory Committee of the Rhode Island Medical Society;
Infectious Diseases Consultant - Rhode Island Department of Health.
Consultant at Sexually Transmitted Diseases Clinic - Rhode Island
Department of Health
Rabies Control Committee, Lyme Disease Control Committee and
Mosquito Control Committee, Rhode Island Department of Health

Associate:

Clinical Septic Shock Study Group - Cleveland Clinic Foundation - Clinical
Evaluation Committee (Co-Chairperson)

Reviewer:

American Journal of Pathology
American Journal of Physiology
Antimicrobial Agents and Chemotherapy
Archives of Internal Medicine
British Medical Journal - Gut
Cancer Research
Chest
Clinical Infectious Diseases
Critical Care Medicine
Infection and Immunity
Journal of the American Medical Association
Journal of Clinical Microbiology
Journal of Clinical Investigation
Journal of Endotoxin Research
Journal of Infectious Diseases
Lancet
Journal of Immunology
Reviews of Infectious Diseases
Southern Medical Journal
Book Reviews:
Journal of The American Board of Family Practice
New England Journal of Medicine

Director:

Division of Validated Animal Models: Brown University/University of
Rhode Island Cooperative Center of Antimicrobial Research

Graduate and Post-Graduate Research Faculty Advisor:

1. J. Bellingham - Medical Research Council of the United Kingdom -
Advanced Fellowship Training in Critical Care Medicine and
Infectious Diseases project - animal models in septic shock research
(Co-preceptor with Dr. C.J. Fisher, Cleveland, Ohio) - 1991.

2. G. Victor - Laboratory research supervisor for 1 year. Fellowship grant in sepsis research. Project - Combination immunotherapy sepsis Celltech Ltd., Slough, U.K. - 1992.
3. R.L.C. Romulo - Laboratory research supervisor for 2 year fellowship grant in monoclonal antibody research. Project - Anti-endotoxin monoclonal antibodies in gram-negative sepsis. Xoma, Berkeley, CA 1993-1994.
4. J. Orange, M.D., Ph.D. Program at Brown University School of Medicine. Ph.D. thesis project on interleukin-12 modulated effects chronic viral infection - 1996.

Medical Advisory Board of Directors:

Center for Hope Care Center, Monrovia, Liberia. R. Meyers, Director

Visiting Professor:

1. Lecture: "Virulence Factors in E. coli Urinary Tract Infection." Winthrop University; Nassau County Hospital, Mineola, New York, September 18, 1986.
2. Lecture: "Immunotherapy in Gram Negative Sepsis." Rose Memorial Hospital, University of Colorado Health Sciences Center, Denver, Colorado, May 3, 1988.
3. Lecture: "Genetics of Methicillin Resistant S. aureus." University of Arkansas School of Medicine, Little Rock, Arkansas, May 5, 1988.
4. Lecture: "Monoclonal Antibody Therapy in Experimental Pseudomonas Sepsis." Celltech Limited Conference in Septic Shock, Slough, United Kingdom, May 24, 1988.
5. Lecture: "Current Treatment of Septic Shock." Medical College of Georgia, Eisenhower Army Medical Center, Augusta, Georgia, March 23, 1990.
6. Lecture: "Opportunistic Fungal Infection." New York Medical College, Lincoln Hospital, New York, New York, April 18, 1990.
7. Lecture: "Infectious Disease Rounds." Cleveland Veteran's Administration Medical Center, Case Western Reserve University, Cleveland, Ohio. September 8, 1990.
8. Lecture: "BPI, the next wonder drug for sepsis?" Walter Reed Army Institute of Research. Walter Reed Army Medical Center, Washington, DC. January 14, 1992
9. Lecture: "Multi-organ dysfunction syndrome of sepsis" John Tyler Memorial Lecture for the Massachusetts Thoracic Society. Boston, Massachusetts, April 9, 1992.

10. Lecture: "The next generation of immunotherapeutic agents in the management of septic shock. Robert Wood Johnson Medical School, Camden, New Jersey. March 11, 1993
11. Lecture: "BPI as an endogenous anti-endotoxin protein." Paris V University. Paris, France. March 26, 1993.
12. Lecture: "Penicillin-resistant strains of invasive Streptococcus pneumoniae." Makati Medical Center, University of the Philippines. Manila, Philippines, May 12, 1994.
13. Lecture: "Clinical Trials For Sepsis: What's Gone Wrong?" University of Massachusetts Medical Center, Worcester, MA., February 16, 1995.
14. Lecture: "Multidrug resistant bacterial infections in the ICU". Rush-Presbyterian Medical Center, Chicago, Illinois, October 29, 1995.
15. Lecture: "Recent advances in the understanding of the pathophysiology of sepsis." The University Hospital of Malaysia, Kuala Lumpur, Malaysia, July 15-16, 1996.

MEDICAL GRAND ROUNDS:

Memorial Hospital, Miriam Hospital, Hasbro Children's Hospital, Women and Infants Hospital, Landmark Hospital, Rhode Island Hospital, Roger Williams Hospital, Veteran's Administration Medical Center, Brown University, Providence, Rhode Island

GRANTS

- | | |
|------|--|
| 1983 | Survey of Extrachromosomal Elements of <u>Legionella Pneumophila</u> Serotype I. Principal Investigator - U.S. Army Grant (\$5,000.00) |
| | The genetics of Exfoliatin B production by <u>Staphylococcus aureus</u> Phage Group I. Principal investigator - U. S. Army Grant. (\$5,000.00) |
| 1984 | Survey of Atmospheric Contamination of Hospital Air by <u>Aspergillus spp.</u> Spores During Hospital Construction. Principal Investigator - U.S. Army Grant. (\$5,000.00) |
| 1985 | The Molecular Epidemiology of Multi-Resistant and Methicillin-Resistant <u>Staphylococcus aureus</u> Infections in Selected Rhode Island Hospitals. Principal Investigator - Rhode Island Foundation. (\$3,500.00) |
| 1986 | The use of a DNA probe for iron assimilation to detect its presence in Bacteremic, Urinary, and Stool Isolates of <u>E. coli</u> . Biomedical Research Support Grant - Principal Investigator. (\$8,000.00) |

- 1987 The utility of human monoclonal antibody against coreglycolipid and cachectin in the neutropenic rat model of experimental *Pseudomonas* sepsis. Principal Investigator. Competitive Award. Celltech Limited, Great Britain. (\$76,000.00)
- Heterosexual HIV Transmission in Greater Providence - Principal Investigator - Kenneth H. Mayer - Co-investigator - R01-AI-25828-01, NIAID Grant. (\$2.1 million)
- 1988 The Cloning and Molecular Characterization of a Unique Beta-Lactamase Which Hydrolyzes Imipenem. Principal Investigator - Biomedical Research Support Grant. BMRSG 88-05. (\$6,700.00)
- 1989 Efficacy of antibiotic coated catheters in preventing catheter infections (in vitro and in vivo study) - Principal Investigator. Davol Inc. (\$34,000)
- 1990 Multicenter Prospective study to investigate the safety and pharmacokinetics of four dosage regimens of CB0006 in patients with sepsis syndrome - Co-Principal Investigator - Celltech Ltd. - (\$60,000)
- Virulence determinants and cytokine induction of blood isolates in septic patients - Principal Investigator. Multicenter Septic Shock Study Group - Case Western Reserve University - (\$36,000)
- 1991 The impact of imipenem on the resistance patterns of nosocomial isolates in the Intensive Care Unit. Co-Principal Investigator. Merck-Sharpe and Dohme (\$98,000)
- Preclinical studies of bacteriocidal permeability increasing protein for treatment of septic shock. Principal Investigator. Incyte Pharmaceuticals (\$42,000).
- The potential value of a monoclonal antibody directed against bacterial endotoxin in experimental *Pseudomonas* sepsis. Principal Investigator. Xoma Corporation (\$46,000)
- A multicenter phase II trial of the Use of Interleukin-1 Receptor Antagonist in the Treatment of Sepsis syndrome. Co-Principal Investigator. Synergen-Pharmaco (\$30,000)
- Interleukin-1 Receptor Antagonist in the Treatment of Experimental Septic Shock. Co-Principal Investigator. Synergen Corporation (\$10,000).

- 1992 A Multicenter Phase III Trial of Interleukin-I Receptor Antagonist in Treatment of Sepsis Syndrome. Co-principal investigator. Synergen (\$60,000).
- A multicenter phase II trial of a monoclonal F(ab)₂' antibody, MAK195F, in the treatment of sepsis. Co-Principal Investigator. Knoll Pharmaceuticals (\$550,000).
- The efficacy of a chimeric anti-TNF monoclonal antibody in the treatment of gram-positive and gram-negative sepsis. Principal Investigator. Celltech Ltd. (\$38,000)
- A Phase II Study of the Human Recombinant Fusion Proteins TNF R1: Fc IgG in the Treatment of Sepsis. Immunex (\$45,000) Principal Investigator.
- 1993 Pre-clinical Investigation of BPI as a Therapeutic Agent in Gram-Negative Infections. Incyte (\$59,000) Principal Investigator.
- CRF as a Therapeutic Agent in Experimental Gram-Negative Sepsis. Principal Investigator. NTI (\$47,000).
- A Multicenter Second Phase III trial of Interleukin-1 Receptor Trial in Severe Sepsis and Septic Shock. Co-principal Investigator, Synergen (\$60,000).
- Analysis of Endotoxin Levels in Septic Patients. Principal Investigator. Synergen (\$10,000).
- 1994 Utility of Limulus Endotoxin neutralizing Protein in the Neutropenic Rat Model of Gram-Negative Sepsis. Associates of Cape Cod - Principal Investigator (\$32,000).
- The North American Multicenter Sepsis Trial of a Murine Anti-TNF Monoclonal Antibody (NORASEPT II). Principal Investigator, Brown affiliated hospitals - Miles-Bayer (\$138,000).
- 1995 Differential Endotoxin Release in Relationship to Beta- Lactam Therapy for Gram-Negative Bacteremia. Merck Research Laboratory - Principal Investigator. (\$38,000)
- Potential Clinical Utility of High Density Lipoprotein as an Anti-endotoxin Agent in Sepsis. Co-principal investigator. Alpha Therapeutics (\$28,000)

Interleukin-11 as a Potential Therapeutic Agent in Experimental Sepsis and Neutropenia. Genetics Institute. Principal Investigator (\$54,000).

A Comparative Study of Differential Antibiotic-Induced Endotoxin Release in Patients With Urosepsis. Principal Investigator. Investigator Initiated IND# 48, 987. (\$85,000)

1996 Antibiotic-induced Endotoxin release and the host inflammatory response; in vitro and in vivo correlations. Principal Investigator, Merck Research Laboratory (\$28,000).

A phase II clinical evaluation of VP643843 a new experimental antiviral agent in the treatment of enteroviral meningitis. Principal Investigator, ViroPharma (\$58,000)

Combination immunotherapy with G-CSF and interleukin-11 in the treatment of sepsis in chemotherapy induced neutropenia. Principal Investigator, Genetics Institute, (\$29,000).

Anti-endotoxin compounds in the prevention and treatment of experimental intra-abdominal sepsis. Merck Research Laboratories. Principal Investigator (\$28,000).

1997 A phase I clinical trial of anti-endotoxin subunit vaccine. Co-Investigator, National Institutes of Health (\$186,000) pending.

PEER REVIEWED PUBLICATIONS

Original Papers

1. Opal, SM, Cross AS, Gernski P. K antigen and its effect on serum sensitivity of rough E. coli. Infection and Immunity 37(3):956- 960, 1982.
2. Cross AS, Opal SM, Kopecko DJ. Progressive increase in antibiotic resistance of gram negative bacterial isolates at Walter Reed Hospital, 1976-1980. Archives of Internal Medicine 143:2075-2080, 1983
3. Piziak MV, Woodbury C, Berliner D, Takafuji E, Kirkpatrick J, Opal SM, Tramont E. Resistance trends of Neisseria gonorrhoeae in the Republic of Korea. Antimicrobial Agents and Chemotherapy 25(1):7-9, 1984.

4. Willis SM, Opal SM, Fitzpatrick JE. Cytophagic histiocytic panniculitis. Archives of Dermatology 121:910-913, 1985.
5. Witte MC, Opal SM, Gilbert JG, Pluss JL, Thomas DA, Olsen JD, Perry ME. Incidence of fever and bacteremia following transbronchial needle aspiration. Chest, 89:85-88, 1986.
6. Opal SM, Asp A, Cannady P, Morse P, Burton L, Hammer P. Efficacy of infection control measures during a nosocomial outbreak of disseminated aspergillosis associated with hospital construction. Journal of Infectious Diseases 153 (3):634-637, 1986.
7. Goodwin R, Opal SM. Polymicrobial bacteremic pneumonia: A report of three cases caused by Staphylococcus aureus and Streptococcus pneumoniae. American Review of Respiratory Disease. 136:1005-1006 1987.
8. Opal SM, Cross AS, and Palmer M, and Almazon R. Group B Streptococcal infection in infants and adults: Contrasts and Comparisons. Archives of Internal Medicine 146:641-645, 1988.
9. Opal SM, Cross AS, Gemski P: Survey of purported virulence factors of E. coli isolated from human blood, urine, and stool specimens. European Journal of Clinical Microbiology and Infectious Diseases 7:425-428, 1988.
10. DeBuono B, Brondum J, Kramer J. Gilbert R, and Opal S.: Plasmid serotypic and enterotoxin analysis of Bacillus cereus in an outbreak setting. Journal of Clinical Microbiology. 26:1571-1574, 1988.
11. Opal SM, Johnson A, Cross A,. Staphylococcal scalded skin syndrome in two immunocompetent adults caused by exfoliatin B producing Staphylococcus aureus. Journal of Clinical Microbiology 26:1283-1286, 1988.
12. Opal SM, Boyce JM, Medeiros AA, Mayer KH, Lyhte LW. Modification of homogeneous resistance in a methicillin resistant strain of Staphylococcus aureus by acquisition of a beta-lactamase plasmid. Journal of Antimicrobial Chemotherapy 23:315-325, 1989.
13. Collins HH, Cross AS, Dobek A, Opal SM, McClain JB, Sadoff JC: Oral ciprofloxacin and anti-lipopolysaccharide monoclonal antibody protect neutropenic rats from lethal infection with Pseudomonas aeruginosa. Journal of Infectious Diseases 159:1073-1082, 1989.
14. Opal S. M., Mayer K. H., Roland R., Brondum J., Heelan J., Lyhte L. Investigation of a foodborne outbreak of Salmonellosis among hospital employees. American Journal of Infection Control 17:141-147, 1989.

15. DeBuono, B. Opal, SM, Sarafian S, Lyhte, LW. Analysis of an outbreak of Penicillinase-producing Neisseria gonorrhoeae in Rhode Island, 1987. Journal of Clinical Microbiology, 27:2125-2127, 1989.
16. Cronan J, Marcello A, Horn D, Robinson, Dorfman G, Opal S. Antibiotics and nephrostomy tube care: development of bacteruria. Radiology 172:1041-1042, 1989.
17. Cronan J, Horn D, Marcello A, Robinson A, Paoletta L, Lambiose R, Haas R, Opal S, Dorfman G. Antibiotics and nephrostomy tube care: Development of bacteremia. Radiology 172:1042-1045, 1989.
18. Boyce JM, Potter-Bynoe G, Opal SM, Dziobek L, Medeiros AA. A common source outbreak of Staphylococcus epidermidis infections among patients undergoing open heart surgery. Journal of Infectious Diseases 161:493-499, 1990.
19. Opal SM, Cross AS, Gemski P, Lyhte LW. Aerobactin and alpha-hemolysin as potential virulence factors in E. coli isolated from human blood, urine, and stool. Journal of Infectious Diseases 161:747-749, 1990.
20. Opal SM, Cross AS, Bodmer MW, Palardy JE, Victor GH, Monoclonal antibody directed against TNF protects neutropenic rats from lethal pseudomonas sepsis. Journal of Infectious Diseases 161:1148-1152, 1990.
21. Opal SM, Mayer KH, Stenberg M, Blazek J, Mikolich, Dickensheets D, Lyhte LW, Trudel R, Musser JM. Nosocomial colonization of health care workers by endemic multiply resistant bacterial pathogens. Infection Control and Hospital Epidemiology. 11:479-485, 1990.
22. Neill M.A., Opal S.M., Giusti R.A., White R., Culpepper L., Mayer K.H. Lack of efficacy of ciprofloxacin in preventing gastrointestinal carriage in Salmonellosis. Annals of Internal Medicine; 114:195-199, 1991.
23. Victor GH, Opal SM. Spontaneous bacterial peritonitis: analysis and outcome. Canadian Journal of Infectious Diseases 2(4):147-154, 1991.
24. Opal S.M., Cross A.S., Sadoff J.C., Collins H.H., Victor G.H., Palardy J., Bodmer M. The efficacy of anti-LPS and anti-TNF monoclonal antibodies in experimental Pseudomonas sepsis. Journal of Clinical Investigation, 88:885-890, 1991.
25. Weist P, Opal SM, Olds GR, Romulo R. The characteristics of malaria in Rhode Island, 1985-1990. American Journal of Medicine 91:30-36, 1991.

26. Heelan J., Opal SM, Brissette E. The impact of converting to a biphasic culture medium in the incidence of Pseudobacteremia. Diagnostic Microbiology and Infectious Diseases. 1992; 15:5-11.
27. Horn D.L., Opal S.M. Computer assisted review of antibiotic selection for bacteremia. Infectious Diseases and Clinical Practice. 1:169-173, 1992.
28. Boyce JM, Opal SM, Potter-Bynoe G, LaForge RG, Zervos MJ, Furtado G, Victor G, Medeiros AA. Emergence and nosocomial transmission of ampicillin-resistant enterococci. Antimicrobial Agents and Chemotherapy 36:1032-1039, 1992.
29. Kim K.S., Was C.A., Cross A.S., Opal S.M. Modulation of blood-brain barrier permeability by tumor necrosis factor and antibody to tumor necrosis factor in the rat. Lymphokine and Cytokine Research. 11:293-298, 1992.
30. Cross A.S., Opal S.M., Sadoff J., Palardy J.E., Bodmer M. Combination immunotherapy in experimental Pseudomonas sepsis. Journal of Infectious Diseases 167:112-118, 1993.
31. Romulo RLC, Opal SM, Palardy JE. Efficacy of anti-endotoxin monoclonal antibody alone or in combination with ciprofloxacin in neutropenic rats with Pseudomonas sepsis. Journal of Infectious Diseases 167:126-130, 1993.
32. Fisher CJ, Opal SM, Dhainaut JF, Stephens S, Zimmerman J, Nightengale P, Harris S. et al. Influence of a murine anti-TNF monoclonal antibody (CB0006) on cytokine levels in patients in sepsis. Critical Care Medicine 21:318-327, 1993 .
33. Richards MJ, Rittman M, Gilbert TT, Opal SM, Debuono B, Neill RJ, Gemski P. An unusually severe foodborne outbreak caused by Staphylococcal enterotoxin A. Public Health Reports 108:765-771, 1993.
34. Knaus WA, Harrell FE, Fisher CJ, Jr., Wagner DP, Opal SM, Sadoff JC, Hein M, Walawander CA, Conboy K, Grasela JH. The clinical evaluation of new drugs for sepsis: A prospective study design based on survival analysis. Journal of the American Medical Association 270:1233-1241, 1993
35. Boyce JM, Opal SM, Potter-Bynoe G, Medeiros AA. Spread of methicillin-resistant S. aureus in a hospital after exposure to a health care worker with chronic sinusitis. Clinical Infectious Diseases 17:496-504, 1993.
36. Hewlett D, Franchini D, Horn D, Alfalla C, Lue Y, Rodriguez M, Roberto M, Yap R, Dipietro D, Peterson S, Eisenberg H, Opal S. An outbreak of multi-drug-resistant tuberculosis at a New York City Hospital. Morbidity and Mortality Weekly Report. June 11, 1993; Volume 42 (22): 427-434, 1993.

37. Cross AS, Opal SM, Sadoff JC, Gemski P. Choice of bacteria in animal models of sepsis. Infection and Immunity 61:2741-2747, 1993.
38. Fisher CJ, Slotman G, Opal SM, Pribble JP, Bone RC, Emmanuel G, Ng D, Bloedou DC, Catalano MA. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome. Critical Care Medicine 22:12-21, 1994.
39. Fisher C.J., Marra M., Palardy J.E., Marchbanks C.R., Scott R., Opal S.M. Bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: A placebo-controlled study. Critical Care Medicine 22:553-558, 1994.
40. Pololi LH, Coletta EM, Kern DG, Davis S, Kiessling LS, Garber CE, Entin EJ, Opal SM, Rakowski W. Developing a competency-based preventive medicine curriculum for medical schools. American Journal of Medical Education 1:1-28, 1994.
41. Bhattacharjee AK, Opal SM, Palardy JE, Drabick JJ, Collins H, Taylor R, Cotlon A, Cross AS. Affinity purified E. coli J5 LPS-specific IgG protects neutropenic rats against gram-negative bacterial sepsis. Journal of Infectious Diseases 170:622-629, 1994.
42. Horn DL, Hewlett D. Jr., Haas WH, Butler WR, Crawford JT, Alfalla C, Tan E, Levine A, Nayak A, Peterson S, Opal SM. Superinfection with rifampin-isoniazid-streptomycin-ethambutol (RISE)-resistant tuberculosis in three AIDS patients: Confirmation by polymerase chain reaction fingerprinting. Annals of Internal Medicine 121:115-116, 1994.
43. Suitters AJ, Foulkes P, Opal SM, Palardy JE, Emtages JS, Rolfe M, Stevens S, Morgan A, Holt A, Chaplin L, Shaw N, Nesbitt AM, Bodmer MW. Differential effect of isotype on efficacy of an anti-TNF-alpha chimaeric antibody in experimental septic shock. Journal of Experimental Medicine 179:849-856, 1994.
44. Boyce JM, Opal SM, Chow JW, Zervos MJ, Potter-Bynoe G, Sherman CB, Fortna S, Romulo RLC, Medeiros AA. Outbreak of multi-drug resistant Enterococcus faecium with transferable van B type vancomycin resistance. Journal of Clinical Microbiology 32:1148-1153, 1994.
45. Fisher CJ, Dhainaut J-F, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines HD, Shelly MP, Thompson RW, LaBreque JF, Knaus WA, Sadoff JC, Recombinant human interleukin-1 receptor antagonist reduces the mortality of patients with sepsis syndrome as a function of disease severity: A randomized double-blind placebo controlled trial. Journal of the American Medical Association 271:1836-1843, 1994.
46. Opal SM, Marra MN, McKelligan B, Fisher CJ, Palardy JE, Scott R. Relative concentrations of endogenous endotoxin binding proteins in infected body fluids. Lancet 344:429-431, 1994.

47. Fisher CJ, Opal SM, Lowry SF, Sadoff JC, LaBrecque JF, Donovan HC, Lookabaugh JL, Lemki J, Pribble JP, Stroma SC, Vigers GP, Russel DA, Thompson RC. Role of interleukin-1 and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. Circulatory Shock 44:1-8, 1994.
48. Rice S, Palardy JE, Thornton L, Heintz R, Opal SM. Clinical, laboratory and management features of a statewide outbreak of enterovirus meningitis. Clinical Infectious Diseases 20:931-937, 1995.
49. Horn DL, Hewlett D, Alfalla C, Pella P, Franchini D, Opal SM. Limited tolerance of Ofloxacin and PZA prophylaxis in health care workers following exposure to RISE resistant tuberculosis. Infectious Diseases in Clinical Practice 4:219-225 1995.
50. Orange J, Salazar-Mather T, Opal SM, Wolf S, Spencer RL, McEwen B, Biron CA. Mechanism of interleukin-12 mediated toxicities during experimental viral infections: role of TNF and glucocorticoids. Journal of Experimental Medicine 181:901-914, 1995.
51. Hewlett D, Horn DL, Franchini D, Alfalla C, Peterson S, Pella P, Opal SM. Nosocomial infection with multidrug resistant and susceptible tuberculosis in 91 health care workers. Infectious Disease in Clinical Practice, 4:389-393, 1995
52. Coronado B, Yoburn S, Opal SM. Antimicrobial induced D-lactic acidemia following a jejunal bypass procedure. Annals of Internal Medicine 122:839-842, 1995.
53. Horn DL, Hewlett D, Alfalla C, Patel A, Brudney K, Crawford JT, Alland D, Kreiswirth B, Opal SM, Peterson S. Clinical experience with rifampin-isoniazid-streptomycin-ethambutol-resistant tuberculosis. Infectious Diseases in Clinical Practice 5:68-72; 1996.
54. Opal SM, Palardy JE, Jhung JW, Donsky C, Romulo RLC, Parejo N, Marra MN. The activity of LBP-BPI fusion peptide in an experimental model of *Pseudomonas* sepsis. Antimicrobial Agents and Chemotherapy 39:2813-2815, 1995 .
55. Bhattecharjee A, Opal SM, Taylor R, Naso R, Semenuk M, Zollinger W, Moran EE, Young L, Hammack C, Sadoff JC, Cross AS. A non-covalent complex vaccine prepared with detoxified *E. coli* J5 LPS and *Neisseria meningitidis* group B outer membrane protein produces protective antibodies against gram-negative bacteremia. Journal of Infectious Diseases 173:1157-1162, 1996.
56. Opal SM, Cross AS, Jhung J, Palardy JE, Parejo N. Potential hazards of combination immunotherapy in the treatment of experimental sepsis. Journal of Infectious Diseases 173:1415-1421, 1996.

57. Fisher CJ, Jr., Agosti J, Opal SM, Lowry S, Sadoff J, Balk R, Abraham E, Schein R, Benjamin E. A phase II, double-blind, randomized clinical trial of soluble TNF receptor:Fc fusion protein in the treatment of severe sepsis. New England Journal of Medicine 334:1697-1702, 1996.
58. Opal SM, Horn DL, Palardy JE, Parejo N, Jhung J, Bhattacharjee A, Young L. The in vivo significance of antibiotic-induced endotoxin release in experimental gram-negative sepsis. Journal of Endotoxin Research, 3:245-252, 1996.
59. Barna B, Fisher CJ, Starkey BS, Jacobs B, Opal SM. Endotoxin levels in sepsis: comparative analysis of chromogenic and turbidimetric methods. Journal of Endotoxin Research , 1996 (In press).
60. Opal SM, Fisher CJ, Pribble JP, Dhainaut J-F, Vincent JL, Brase R, Lowry SF, Sadoff JC, Slotman, G, Levy H, Balk RA, Shelly MP, Lookabaugh J, Donovan H, LeBreque JF, Baughman R, Norman J, DeMaria E, Matzel K, Abraham E, Seneff M and the rhIL-1ra Sepsis Study Group. The Confirmatory interleukin-1 receptor antagonist trial in sepsis: a phase III randomized, double-blind, placebo-controlled, multicenter trial. Critical Care Medicine, 1996 (in press).

Review Papers

1. Pluss JL, Opal SM. Pulmonary sporotrichosis: review of treatment and outcome. Medicine 65:(3)143-153 1986.
2. Medeiros A, Mayer KH, Opal S. Plasmid mediated beta-lactamases The Antimicrobial Newsletter 5:(9)61-62, 1988.
3. Cross AS, Opal SM, Therapeutic intervention in sepsis with antibody to endotoxin: is there a future? Journal of Endotoxin Research 1(1): 57-69, 1994.
4. Opal SM. Lessons Learned in Recent Clinical Trials for Sepsis. Journal of Endotoxin Research 2:221-226, 1995.
5. Opal SM, Fisher CJ. Clinical trials in septic shock. Where did they fail? Intensivmedizin und Notfallmedizin, 33:160-166, 1996.
6. Horn D, Opal SM, Smith D. Antibiotics, endotoxin and cytokine release, a complex and dynamic process. Scandinavian Journal of Infectious Diseases, 1996 (in press)

Case Reports

1. Opal SM, Pittman DL, Hofeldt F. Testicular sarcoidosis. American Journal of Medicine 66:147-150, 1979.

2. Wilkerson RD, Taylor DC, Opal SM, Curl WW. Nocardia asteroides sepsis of the knee. Clinical Orthopedics and Related Research 197:206-208, 1985.
3. Harpster WH, Gonzales C, and Opal SM. Pansinusitis caused by the fungus Drechslera. Otolaryngology - Head and Neck Surgery 93(5):683-685, 1985.
4. Opal SM, Saxon JR. Intracranial infection by Vibrio alginolyticus following head injury in salt water. Journal of Clinical Microbiology 23(2):373-374, 1986.
5. Opal SM, Reller LB, Harrington J, Cannady P. Aspergillus clavatus endocarditis occurring on a normal aortic valve following coronary artery surgery. Reviews of Infectious Diseases. 8(5):781-785, 1986.
6. Bradburne M, Ettensohn D, Opal SM, McCool D: Pneumocystis carinii pneumonia limited to the upper lobes in AIDS. Thorax 44:591-593, 1989.
7. Horn DL, Hewlett D, Peterson S, Sabido D, Opal SM. RISE- resistant tuberculosis meningitis in an AIDS patient. Lancet 341, 177-178. 1993.
8. Meyerhoff A, Renzi R, Opal SM. Fatal Clostridial sepsis in a patient with no underlying cause of illness. Clinical Infectious Diseases 20:1066-1067, 1995.

BOOK AND MONOGRAPH CHAPTERS

1. Opal SM. Therapy of bacterial meningitis. In Conn's Current Therapy. W. B. Saunders Co. Philadelphia, PA. 70-74, 1986.
2. Mayer KH, Opal SM: Opportunistic infections in patients with HIV infections. In: Color Atlas of AIDS. Alvin Friedman-Kien (editor). 125-150, 1989.
3. Mayer KH, Opal SM, Medeiros AA. Mechanisms of antibiotic resistance. In Principles and Practice of Infectious Diseases, Mandell, Douglas, and Bennett (ed.) 3rd Edition; 218-227, 1989.
4. Opal SM. The Treatment of Pyelonephritis. In Conn's Current Therapy. 622-624, 1990.
5. Mayer KH, Opal SM. Unusual Nosocomial Infections. Infectious Disease Clinics of North America 3:883-899, 1989.
6. Opal SM, Mayer KH, DeBuono B, Infectious Diseases: A Guide to Health Care in Rhode Island. Anagnostou (ed). 55-61, 1988.
7. Opal SM. Treatment of pyelonephritis. In Conn's Current Therapy 643-645, 1991.

8. Cross AS, Sadoff JC, Opal SM, Bhattacharjee AK, Cryz SJ, Immunotherapy for septic shock: A process-oriented approach, Root and Sande In Contemporary Issues in Infectious Diseases. Root, RK and Sande, MA (Eds) Treatment of Serious Infections in the 1990s. Churchill Livingstone, New York, 77-91, 1991.
9. Opal SM. Interleukin-1 receptor antagonist as a therapeutic modality in sepsis. In: Yearbook of Intensive Care and Emergency Medicine. J-L Vincent (ed) Springer-Verlag, Berlin, Germany 107-114, 1993.
10. Opal SM, Marra M, Cross AS: Interaction of Bactericidal/ Permeability-Increasing Protein with LPS and experience with animal models of gram-negative infections. In: Mediators of Sepsis. Baumgartner, Calandra and Carlet (ed) Flammarion Publishers, Paris, France, 37-46, 1994.
11. Opal SM, Mayer KH, Medeiros, AA. Antibiotic Resistance - Problems in Antimicrobial Therapy. In Textbook of Therapeutic Medicine Cunha (ed), (In press) 1996.
12. Mayer KH, Opal SM, Medeiros AA. Mechanisms of antibiotic resistance. In. Principles and Practice of Infectious Diseases, 4th edition, Mandell, Douglas, Bennett (ed) Churchill Livingstone, New York, pp. 212-225, 1995.
13. Mayer KH, Opal SM. Opportunistic infections in AIDS. In: Color Atlas of AIDS, second Edition, Friedman-Kien (ed) W.B. Saunders Company, Philadelphia, Pennsylvania 1996 (p. 9-34).
14. Opal SM. Urinary Tract Infections in The Intensive Care Unit. In. Intensive Care Medicine, 3rd edition. JM Rippe, RS Irwin, MP Fink, FB Cerra (ed). Little, Brown and Company, Boston, Massachusetts, 1152-1162, 1996.
15. Opal SM. Interleukin-1 receptor antagonist in sepsis. In: Therapeutic Modulation of the Cytokines, CRC Press, London, United Kingdom, M. Bodmer and W. Henderson (ed) 196-219, 1996.
16. Opal SM, Fisher CJ, Jr., Pribble J. Treatment of sepsis with Interleukin-1 receptor antagonist: Sepsis: current perspectives in pathophysiology and therapy. K. Reinhart, K Eyrich, C. Sprans (Eds) Springer-Verlag, Berlin (Vol 18) 1994: p 382-390.
17. Opal SM, Fisher CJ, Dhainaut J-F, Bodmer M. Anti-TNF strategies - the CB6 sepsis study. Multi-organ failure, multi-organ dysfunction syndrome and systemic inflammatory response syndrome (2nd edition) E. Faist (ed) Pabst Science Publishers, Zagreb, Croatia p 1-7, 1996.
18. Fisher CJ, Opal SM, Marra MN. Bactericidal Permeability- Increasing Protein: A potent naturally occurring anti-endotoxin protein. In: Update in Intensive Care Medicine M. Lamy and L.G. Thijs (editors). Springer-Verlog, Berlin (Vol.16) 339-344, 1994.

19. Opal SM. Novel therapeutic agents: Why did they fail? In Yearbook of Intensive Care and Emergency Medicine J-L Vincent (editor), Springer-Verlag, Berlin, pp.425-435, 1995.
20. Opal SM, Zinner SH. Sepsis and Bacteremia. In: Atlas of Infectious Diseases. R Fekety and G Mandell (editors). Churchill Livingstone, Philadelphia, PA, 3.1-3.14. 1996.
21. Bhattacharjee A, Cross AS, Opal SM, Warren HS, Sadoff JC. New trends in Escherichia coli 0111:B4 J5 mutant (Rc chemotype) vaccine development for use in gram-negative bacillary sepsis. in Novel Therapeutic Strategies in the Treatment of Sepsis. D. Morrison and J Ryan (editors). pp.1-12, 1995.
22. Fisher CJ, Opal SM, Lowry SF, LaBrecque JF, Donovan HC, Lookabaugh JL, Lemke J, Pribble JP, Stromatt JC, Vigers GP, Russell DA, Thompson RC. The role of interleukin-1, and the therapeutic potential of interleukin-1 receptor antagonist in sepsis. In Cytokines and Anticytokines. Lesslauer H (editor); 1997 (in press).
23. Marra MN, Opal SM, Scott RW, Seilhamer JJ. The use of bactericidal/permeability-increasing protein and related proteins as potential therapeutic agents for the treatment of endotoxin- related disorders. In: Novel Therapeutic Strategies in the Treatment of Sepsis. D. Morrison and J. Ryan (editor). pp.33-54, 1995.
24. Opal SM, Keith J, Interleukin-11 as a potential therapeutic modality in sepsis. In Yearbook of Intensive Care and Emergency Medicine. J-L Vincent (editor) pp. 111-118, 1996.
25. Opal SM, Abraham E. The use of soluble cytokine receptors and anticytokine antibodies in infectious diseases. In: Cytokines in Infectious Diseases. van Deuren, Gannon, Griffin, van der Meer (editors) 1996 (in press).
26. Opal SM. Criticisms of Clinical Trials of Sepsis and Organ Failure. Organ Failure Academy. A. Gullo (editor) Vol. 4, 1996, p. 29-41.
27. Cross AS, Sadoff JC, Gemski P, Jr., Opal SM. Selection of bacteria for animal models of sepsis. In. Advances in The Treatment of Radiation Injuries. TJ MacVittie, JF Weiss, D Browne (editors). Elsevier Science Inc., New York. pp. 119-126, 1996.
28. Opal SM. Splenectomy and Splenic Dysfunction. In: Infectious Diseases. D. Armstrong and J Cohen (editors). Times-Mirror International Publishers, 1998 (in press).
29. Opal SM, Scott D. Endocarditis. In: Practical Cardiology. AH Kahn (editor) 1997 (in press).
30. Opal SM. Basic elements which control the human immune response. In: Critical Care Medicine. APICE. A. Gullo (editor) Fogliazza Publishers, Milano. 11th edition. 1997 (in press).

OTHER PUBLICATIONS

1. Opal SM. Fatal aspergillosis outbreak controlled by strict measures. Hospital Infection Control. Vol. 14 (4):59-60, 1986.
2. Mayer KH, Opal SM. Antimicrobial therapy in patients with malignancies. Cancer and Metastasis Reviews 5:271-293, 1987.
3. Mayer KH, Opal SM. Treatment prospects and vaccine development in AIDS. Rhode Island Medical Journal. 70:27-33, 1987.
4. Mayer KH, Opal SM. Antibiotic resistance complicating nosocomial infections. Infections in Surgery 6:661-665, 1987.
5. Mayer KH, Opal, SM: Antibiotic resistance: A factor in nosocomial infections. Infections in Medicine 4:453-458, 1987.
6. Opal SM. Is the decline in autopsy rates bad news for infection control? Hospital Infection Control. Vol. 14(3): 45-46, 1987.
7. Opal SM. Chronic EBV infection and the chronic fatigue syndrome. Rhode Island Department of Health Disease Bulletin. 23:1-4, 1987.
8. DeBuono B, Opal SM. (editors) AIDS: A Guide to Rhode Island Physicians. RIDH, September, 1989.
9. Opal SM, Weist PM, Olds GR. Traveler's diarrhea: methods of prevention and treatment. Rhode Island Medical Journal 73:199-206, 1990.
10. Weist PM, Opal SM, Olds GR. Malaria: The killer from overseas. Rhode Island Medical Journal 73:207-214, 1990.
11. Romulo R, Weist PM, Opal SM, Olds GR. Travel to developing countries: predeparture advice. Rhode Island Medical Journal 73:181-188, 1990.
12. Opal SM. Infection prevention in neutropenia. Current Opinion of Infectious Diseases. 3(2):203-207. 1990.
13. Opal SM. Foodborne outbreaks of salmonellosis among hospital employees. Infectious Diseases Digest 2:29-30, 1990.
14. Emgushov RT, Opal SM. Update of Infectious Diseases - 1990. Rhode Island Medical Journal 1990; 73:517-523.

15. Opal SM. Prevention of infection in neutropenia. Current Opinion of Infectious Diseases. 4:359-364, 1991.
16. Opal SM, Reflections on the Hippocratic Oath. Rhode Island Medical Journal. Vol 74:553-554, 1991.
17. Abalo T, Opal SM, Infection Prevention in neutropenia. Contemporary Internal Medicine. 5:(11) 32-41, 1993.
18. Young LS, Bone RC, Opal SM, Wenzel RP. New immunotherapeutic strategies against gram-negative infections. Scientific Symposium Proceeding Pragmaton Press, Chicago, 3-8, 1993.
19. Opal SM (Editor). Pathophysiology of sepsis/septic shock monograph, text and slide files. Triclinica, New York, New York 1993.
20. Opal SM, Palardy JE, Romulo RLC, Cross AS. Tumor necrosis factor receptor fusion protein in the treatment of experimental Pseudomonas sepsis. Pseudomonas New Letter 18:5. 1993.
21. Sanieel MC, White M, White F, Castillo T, Superable J, Perez A, Dayrit M, Opal SM, Donsky C. Multi-drug resistant typhoid fever in the Philippines: highlights of an outbreak. Journal of the American Medical Association Supplement (S.E. Asia) 1994; 10:328-333.
22. Cross AS, Opal SM. Endotoxin's role in gram-negative bacterial infection. Current Opinion in Infectious Diseases 8:156-163, 1995.
23. Opal SM. Probing to bone as a diagnostic method in pedal osteomyelitis in diabetic patients. Journal of Diabetes Care, September 1996 (in press).
24. Dellinger P, Opal SM, Rotrosen D, Suffredini AF, Zimmerman J, (editors) NIH Conference: The Future of Sepsis Research: From the Bench to Bedside. Chest 1996 (in press).
25. Opal SM. Infectious disease challenges in the 1990's. Rhode Island Medical Journal 79:100-105, 1996.
26. Opal SM. Encountering endotoxins: an emerging focus of therapy. Monograph for the 7th International Congress for Infectious Diseases. Oxford Clinical Publications. June 10, 1996.

LETTERS AND REVIEWS

1. Morse PL, Opal SM. Adsorption of Clostridium difficile antiserum for rapid detection of toxin. (Letter) Diagnostic Microbiology and Infectious Disease, 2:169, 1984.
2. Pluss JL, Opal SM. Ketoconazole in the treatment of pulmonary Pseudallescheria boydii infections. (Letter) Chest, 87:843, 1985.
3. Opal SM. Book Review: New England Journal of Medicine, 315(24): 1558-1559, 1986.
4. Opal SM. Book Review. New England Journal of Medicine. 316 (11): 697, 1987.
5. Singh V., Opal SM: Rocky Mountain Spotted Fever in Rhode Island. Rhode Island Medical Journal 71: 155-158, 1988.
6. Victor G, Opal SM, Mayer KH Bramley J: Staphylococcal pyomyositis in AIDS. (Letter) Archives of Internal Medicine; 149:705-706, 1989.
7. Bradburne RM, Etensohn DB, Opal SM, McCool DF: Relapse of pneumocystis pneumonia in the upper lobes during aerosol pentamidine prophylaxis. (Letter) Thorax 1989;44:1059.
8. Cross AS, Opal SM, Group B Streptococcal sepsis. (Letter) Journal of the American Medical Association. 268:2651, 1992.
9. Skolnick AA, Opal SM, Bone RC, Maldawar LL. Medical New and Perspectives; Researchers try new definitions, New therapies in an effort to solve growing problem of sepsis. Journal of the American Medical Association. 269:838-843, 1993.
10. Horn DL, Hewlett D, Alfalla C, Peterson S. Opal SM. Limited Tolerance of ofloxacin and pyrazinamide prophylaxis for rifampin-isoniazid-streptomycin-ethambutol (RISE)-resistant tuberculosis infection. New England Journal of Medicine 330:1241, 1994.
11. Fisher CJ, Opal SM. Tumor necrosis factor in critical illness: (reply). Critical Care Medicine 22:1702-1703. 1994.
12. Hunt V, Opal SM. Book Review: Manson's Tropical Diseases. Journal of The American Board of Family Practice 9:394-395, 1996.
13. Fisher, CJ, Agosti JM, Opal SM. Tumor necrosis factor receptor:Fc fusion protein in septic shock. New England Journal of Medicine, 335:1067-1069, 1996.

MANUSCRIPTS SUBMITTED

1. Horn DL, Hazlett D, Opal SM. Tuberculous meningitis and nosocomial transmission of RISE resistant tuberculosis. Clinical Infectious Disease 1997 (submitted).
2. Opal SM, Palardy JE, Lemke J, Knaus W, Dubin P, Fisher CJ, Vincent J-L. Endotoxemic in sepsis: clinical, therapeutic prognostic implications. JAMA 1997 (submitted).
3. Opal SM, Jhung J, Keith J., Jr., Palardy JE, Parejo N, Schaub J. Therapeutic effects of interleukin-11 in immunocompromised animals with experimental gram-negative sepsis. Infection and Immunity, 1997 (submitted).
4. Ruzek M, Opal SM, Salazar-Mather TP, Biron CA. The role of interleukin-6 in the regulation of corticosteroid synthesis during systemic infection. Journal of Immunology, 1997 (submitted).

INVITED SPEAKER IN NATIONAL OR INTERNATIONAL SYMPOSIA

1. Philippine Society of Microbiology and Infectious Diseases. 3rd Annual Symposium. "New Concepts of Immunotherapy in Septic Shock." Makati Medical Center, Manila Philippines, May 15, 1991.
2. University of Southern California Conference of Active vs. Passive Antibody Therapy in Treatment of Infectious Diseases. "Anticytokine therapy in Infectious Diseases," Scottsdale, Arizona, June 1, 1991.
3. International Congress of Chemotherapy. "Experience with Monoclonal Antibody Therapy in the neutropenic Rat Model," Berlin, Germany. June 24, 1991.
4. Ruzek MC, Miller AH, Opal SM, Pearce BD, Biron CA. Characterization of early cytokine responses and IL-6 dependent pathway of endogenous glucocorticoid induction during murine CMV infection. J. Immunology 1997 (submitted).
5. National Investigator's meeting at the 31st Annual ICAAC Meeting. "Pre-clinical Studies With Anti-endotoxin Monoclonal Antibodies." Chicago, Illinois, September 28, 1991.
6. University of Virginia. National Symposium for Infectious Disease Specialists. "Advances in Immunomodulator in Sepsis." Jacksonville, Florida, February 23, 1992.
7. International Immunocompromised Host Society, 1992 Meeting. Symposium lecture. "Anticytokine Therapy in Immunocompromised Patients." Boulder, Colorado, June 25, 1992.

8. Interscience Conference on Antimicrobial Agents and Chemotherapy (32nd Meeting) Symposium "Animal models of sepsis, what, if anything do they tell us?" October 14, 1992.
9. Maurice Rapin Colloquia on Endotoxin Pathophysiology and Therapeutic Approaches: "Experience With BPI in Animal Models." Provence, France. November 7, 1992.
10. Maurice Rapin Colloquia on Endotoxin Pathophysiology and Therapeutic Approaches: "Interleukin-1 receptor antagonist as a therapeutic agent." Provence, France, November 8, 1992.
11. Vail Infectious Disease Conference (Annual Meeting Sponsored by University of Colorado Health Sciences Center) Invited Faculty Speaker, March 1-7, 1993.
12. International Symposium on Intensive Care and Emergency Medicine (13th Meeting). "IL-1ra and BPI in the Treatment of Sepsis" Brussels, Belgium, March 23, 1993.
13. The Third IBC Annual Meeting in Advances in the Diagnosis, Prevention, and Treatment of Endotoxemia and Sepsis. "Interleukin-1 receptor antagonist." Philadelphia, PA June 18, 1993.
14. The Fourth International Conference on Endotoxin. "The Role of TNF in Infectious Diseases." Academic Medical Center, Amsterdam, The Netherlands. August 18, 1993.
15. The Fifth International Steglitz Symposium on Sepsis. "Chimeras of LPS binding proteins and bactericidal permeability increasing protein as therapeutic agents in experimental gram-negative sepsis. Berlin, Germany, February 10, 1994.
16. Consensus Conference. Lessons learned from the phase II CB6 anti-TNF monoclonal antibody study. 3rd International Congress on the Immune Consequences of Trauma, Shock and Sepsis. Munich, Germany, March 3, 1994.
17. The Sigma Tau Research Conference. The Potential Utility of L-Carnitine in The Treatment of Human Sepsis and Lactic Acidosis. Rome, Italy, February 18, 1994.
18. The 3rd International Congress on the Immune Consequences of Trauma, Shock and Sepsis. "The Value of Animal Models in Sepsis." Munich, Germany, March 5, 1994.
19. The Philippine College of Physicians Annual Meeting. "Anti-cytokine Therapy in Infectious Disease". Plenary Session speaker. May 11, 1994.
20. 1st International Symposium on the Mediators of Sepsis. Potential role of combination immunotherapy in sepsis. Plenary session. Deauville, France, November 7-8, 1994.

21. European Shock Society Autumn Meeting. "The role of bacterolysis and LPS release." Symposium on Antibiotic Related Endotoxin Release. Deauville, France November 7, 1994.
22. International Symposium of Intensive Care and Emergency Medicine (15th Annual Meeting), "Combination Therapy in Sepsis." Brussels, Belgium, March 21, 1995
23. Cambridge Healthtech Institute Conference: Designing better drugs and clinical trials for sepsis/SIRS. "Lessons learned from clinical trials thus far." Washington DC, February 21-22, 1995.
24. The 15th International Symposium of Intensive Care Medicine Conference. "The Role of BPI in Anti-endotoxin Therapy", Brussels, Belgium, March 22, 1995.
25. Society for Critical Care Medicine Annual Meeting: "Antibiotic-Induced Endotoxin Release." New Brunswick, NJ, October 12, 1995
26. The Fifth Annual Organ Failure Academy Meeting. "The Failure of Recent Clinical Trials of Sepsis." Trieste, Italy, November 19, 1995.
27. The 16th International Symposium on Intensive Care and Emergency Medicine. "The Role of Interleukin-11; Endotoxemia in sepsis; the 2nd phase III IL-1ra sepsis trial." Brussels, Belgium, March 18-21, 1996.
28. International Congress of Infectious Diseases, "Clinical significance of endotoxin release during treatment with gram-negative infections." Hong Kong, June 12, 1996
29. Singapore Society of Intensive Care Medicine. "Sepsis, antibiotics, endotoxin and cytokines." Singapore, July 17, 1996.
30. University of Malaysia - Infectious Disease Division Lecture. "Current understanding of the pathogenesis of sepsis." Kuala Lumpur, Malaysia, July 16, 1996
31. International Congress of Experimental Hematology. "The effect of recombinant human interleukin-11 on the monocyte/macrophage cell line". New York City, New York. August 23, 1996.
32. Anaesthesia, Pulmonary, Intensive Care and Emergency Medicine. Control mechanisms of the human immune response," Trieste, Italy, November 7, 1996.
33. The 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. "The Physiologic role of human interleukin-11 in infections." New Orleans, LA, September 17, 1996.

34. Rockefeller Symposium: "Group A Streptococcal Infections: Why hasn't penicillin resistance developed." Rockefeller Institute, New York, NY, October 7, 1996.
35. The Royal College of Physicians Annual Meeting.... "The Current Treatment of Septic Shock." London, United Kingdom, May 15, 1997.

COURSE DIRECTOR OR SCIENTIFIC ORGANIZING COMMITTEE

1. Brown University Continuing Medical Education Course - Tuberculosis in the 1990's. (Organizing Committee) Providence, RI, November 7, 1990.
2. World AIDS Foundation Grant - Sexually Transmitted Diseases in the AIDS era. (Course Director) Manila, Philippines, May 8-17, 1991.
3. Autumnal Thematic Meeting on Sepsis. (Symposium Scientific Organizing Committee). Deauville, France, November 7-8, 1994.
4. The 5th Annual IBC Conference on Endotoxemia and Sepsis. (Scientific Organising Committee). Review of Preclinical Studies on Endotoxin Shock, Philadelphia, PA June 19-21, 1995.
5. The 35th Annual ICAAC Meeting (Symposium Organizer) - "Clinical trials of sepsis - should we give up?," San Francisco, CA, September 22, 1995.
6. The NIH Workshop on the Future of Sepsis Research. Relevance of Animal Models (Session Coordinator) Bethesda, Maryland, August 3-4, 1995.
7. The 4th International Congress on the Immune Consequences of Trauma, Shock and Sepsis. (Program Organizing Committee) Munich, Germany, March 4-8, 1997.
8. The 16th Annual IBC Conference on Endotoxemia and Sepsis (Scientific Organizing Committee). Endotoxin, Cytokines and Other Mediators of Sepsis. June 24-26, 1996, Cambridge, Massachusetts.
9. The 7th Annual IBC Conference on Endotoxemia and Sepsis. (Scientific Organizing Committee). April 28-30, 1997. Washington, DC.

ABSTRACTS PRESENTED AT REGIONAL, NATIONAL, OR INTERNATIONAL MEETINGS

- 1. Opal SM. Clinical utility of the Raji cell radioimmunoassay for detection of circulating immune complexes. Presentation to the American College of Physicians Meeting, Letterman Army Medical Center, San Francisco, California. January 24, 1979.

2. Opal, SM , Cross AS, Gemski P. The effects of K antigen on serum sensitivity of rough E. coli. Presented at the 82nd Annual Meeting of the American Society for Microbiology, Abstract #B163, Atlanta, Georgia, March 11, 1982.
3. Cross AS, Opal SM , Kopecko DJ. Progressive increase in aminoglycoside resistance in gram-negative bacterial isolates. Presented at the 22nd Interscience Conference on Antimicrobial Agents and Chemotherapy #533, Miami Beach, Florida, October 5, 1982.
4. Pluss JL, Opal SM. Recent experience in the diagnosis and treatment of pulmonary sporothrichosis. Presented at the American College of Physicians meeting, San Francisco, California. October 2, 1984.
5. Witte MC, Opal SM, Gilbert JG. The incidence of bacteremia associated with transbronchial needle aspiration. Presentation at the American College of Physicians Meeting, San Francisco, California, October 2, 1984.
6. Opal SM. Plasmid epidemiology and the dissemination of antimicrobial resistance. Presented at ACP Meeting, San Francisco, California. October 2, 1984.
7. Opal SM, et al. The epidemiology of nosocomial aspergillosis associated with hospital construction. Presented at the 85th Annual Meeting of the American Society for Microbiology, Las Vegas, Nevada. March 3-7, 1985, Abstract #L-28.
8. Opal SM, Cross A, Gemski, P. Survey of purported virulence factors of E. coli isolated from blood, urine, and stool specimens. The 86th Annual Meeting of the ASM, Washington, D.C. March 28, 1986. Abstract # B16.
9. Opal SM, Blaser MJ, Lyhte LW. The Role of plasmids in the expression of serum resistance in Campylobacter fetus. Presented to The Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, October 1, 1986, # 1087.
10. Opal, SM, Lyhte, LW, Boyce, JM, Medeiros, AA, Mayer, KH. The Role of Beta lactamase Plasmids in The Expression of Methicillin Resistance in Staphylococcus aureus. Presented at the Northeast Regional Meeting of The American Society for Microbiology, Lake George, New York. September 26, 1986. #8
11. Mayer KH, Hopkins JD, Opal SM, Ellal JA, O'Brien TF: Molecular evolution of epidemic and endemic aminoglycoside resistant plasmids carrying the ANT(2") gene. Congress on Bacterial and Parasitic Drug Resistance, Bangkok, Thailand, December 10-13, 1986.

12. Opal SM, Cross AS, Palmer M, Almazan R: Group B streptococcal infection in infants and adults: Clinical characteristics and consequences. The 87th Meeting of the American Society for Microbiology, Abstract #L32, Atlanta, Georgia, March 4, 1987.
13. Boyce JM, Potter-Bynoe, Opal SM, Dziobek L, and Medeiros AA. An Epidemic of *Staphylococcus epidermidis* infections following open heart surgery. 27th Annual ICAAC, New York, New York, October 1987. Abstract # 604.
14. Victor GH, Opal SM. Spontaneous bacterial peritonitis: A persistent problem with a high mortality rate. 27th Annual ICAAC, New York, New York, October 1987. Abstract # 1092.
15. Opal SM, Boyce JM, Medeiros AA, Mayer KH, and Lyhte LW. Modification of homogeneous resistance by a beta-lactamase plasmid in a methicillin resistant strain of *Staphylococcus aureus*. 27th Annual ICAAC, New York, New York, October 1987. Abstract # 1026.
16. K. Mayer, F. Tenover, J. Hopkins, J. Ellal, S. Opal, J. Plorde, T. O'Brian. Replacement of the ANT (2") by the AAC (6')-I gene on an endemic, Conjugative plasmid by structural gene transfer while retaining a similar promoter. 27th Annual ICAAC, New York, New York, October 1987. Abstract # 394.
17. Debuono B, Opal SM, Brondum J. Plasmid, serotypic and enterotoxin analysis of *Bacillus cereus* in an outbreak setting. 27th Annual ICAAC, New York, New York, October 1987. Abstract # 1178.
18. Lyhte LW, Opal SM, et al. Investigation of an outbreak of *Salmonella enterocolitis* in hospital employees. Northeast Meeting of the American Society for Microbiology, Sturbridge, Massachusetts, October 23, 1987. Abstract # 11.
19. Harper ME, Lewis JS, Mayer KH, Opal SM, Hogan JJ, Milliman CL, Jonas V, Bhatt RS. Specificity of a DNA probe for *Neisseria gonorrhoeae* used in a rapid, direct test. The 88th Annual Meeting of the American Society for Microbiology. Miami, Florida, May 11, 1988. (Abstract #C 35).
20. Mayer K, Horn A, Mandler H, Mikolich D, Dudley M, Medeiros A, Opal S, Boyce J, Zinner S. Treatment of complicated UTI's with IV, then oral enoxacin. International Congress for Infectious Diseases. Rio de Janeiro, Brazil, April 17, 1988 (Abstract #520).
21. Opal SM, Mayer KH, Stenberg M, Blazek J, Mikolich D, Dickensheets D, Lyhte LW. Colonization of health care workers by multiresistant bacterial pathogens in an endemic hospital environment. The 88th Annual Meeting of the American Society for Microbiology. Miami, Florida May 11, 1988 (#L 34).

22. DeBuono BA, Opal SM, Sarafian SK. Multiple strain of penicillinase-producing Neisseria gonorrhoeae in Rhode Island. 28th Annual ICAAC, Los Angeles, California, October 1988 (Abstract # 1162).
23. Opal SM, Cross AS, Bodmer MW, Palardy JE, Victor GH. Monoclonal Antibody Directed Against TNF Protects Neutropenic Rats from Lethal Pseudomonas Sepsis. The 89th Annual Meeting of The American Society For Microbiology, New Orleans, LA, May 14, 1989 (Abstract # E59)
24. Opal SM, Cross AS, Gemski P, Lyhte LW. Aerobactin and Alpha-Hemolysin as Potential Virulence Factors in Escherichia coli Isolated From Human Blood, Urine, and Stool. The 89th Annual Meeting of The American Society For Microbiology, New Orleans, LA, May 14, 1989 (Abstract # B76).
25. Opal SM, Cross AS, Palardy J, Victor G, Sadoff J, Collins H, Bodmer MW. Effect of anti-TNF Mab and anti-LPS Mab in experimental Pseudomonas sepsis. The 29th Annual ICAAC - Houston, Texas, September 1989 (Abstract #840).
26. Boyce J, Potter-Bynoe J, Opal SM, Medeiros AA. Evidence for nosocomial transmission of ampicillin resistant Enterococcus faecium and Enterococcus raffinosus. The 29th Annual ICAAC - Houston, Texas, September 1989 (Abstract #657).
27. Neill MA, Opal SM, Giusti RA, White R, Culpepper L, Mayer KH. Lack of efficacy of ciprofloxacin in preventing prolonged gastrointestinal carriage following a foodborne outbreak of Salmonellosis. The 29th Annual ICAAC - Houston, Texas, September, 1989 (Abstract #43).
28. Ellis P, DiBenedetto J, Opal S. Staphylococcal scalded skin syndrome as a complication of the treatment of aplastic anemia. 31st Annual Meeting Of The American Society of Hematology. December 1989 (Abstract # 1144).
29. Kim KS, Was, CA, Opal SM, Cross AS. Role of tumor necrosis factor in modulating blood-brain barrier permeability in vivo. American Society of Pediatric Research, Anaheim, California. June 1990 Abstract # 23414.
30. Heelan J., Opal SM, Brissette E., Donahue M. The impact of converting to a biphasic culture system on the incidence of pseudobacteremia. The 90th Annual Meeting of the American Society for Microbiology, Anaheim, California. May 14, 1990. Abstract (#C286)
31. Opal S.M. Lyme Disease Update: Serologic diagnosis of Lyme Disease. (Seminar) Northeast Association of Clinical Microbiology and Infectious Diseases. Danvers, Massachusetts June 13, 1990.

32. Santos-Ocampo, S., Sanieel M., Opal S.M., Palardy J., Lyhte L., Mayer K.H. Clinical characteristics of antibiotic resistant V. cholera O1 El tor in the Philippines. The 30th Annual Meeting, ICAAC, Atlanta, Georgia October 22, 1990 Abstract # 921.
33. Leano F., Opal SM., Sanieel M., . Plasmid analysis of antibiotic resistant Shigella flexneri in the Philippines. 2nd Western Pacific Congress of Infectious Diseases and Chemotherapy. Bangkok, Thailand, December 11, 1990 (abstract # B-1).
34. Fisher CJ, Opal SM, Marra M, Palardy JE, Scott RN. Bactericidal permeability increasing protein neutralizes endotoxin and reduces mortality in experimental sepsis. Critical Care Medicine Annual Meeting, Washington, DC. May 24, 1991.
35. Fisher CJ, Opal SM, Marra MN, Palardy JE, Scott RW. Bacterial/Permeability-Increasing Protein (BPI) Reduces Mortality in Experimental Sepsis. Second International Conference on Shock, Vienna, Austria. June 2-6, 1991.
36. Opal SM, Cross AS, Palardy JE, Bodmer MW. The efficacy of combination immunotherapy in experimental Pseudomonas sepsis. American Federation of Clinical Research National Meeting. Seattle, Washington. May 4-6, 1991 (Abstract # 214A).
37. Opal SM, Fisher CJ, Marra M, Scott R, Palardy JE. Bacteriocidal permeability-increasing protein as a novel therapeutic modality in the treatment of endotoxic shock. American Federation of Clinical Research National Meeting, Seattle, Washington, May 4-6, 1991 (Abstract # 351A).
38. Fisher CJ, Harris S, Bodmer M, Opal SM, Sadoff J, and The Septic Shock Study Group. Clinical experience with an anti-TNF monoclonal antibody in the treatment of sepsis syndrome. Second International Conference on Shock. Vienna, Austria. June 2-6, 1991.
39. Opal SM, Fisher CJ, Cross, AS, Sadoff JC, Palardy JE, Young L, Harris SJ, Stephens S. and the CB6 Study Group. The offending organism, cytokine profile, and outcome in sepsis syndrome. The 31st Annual Meeting ICAAC, Chicago, Illinois, September 29, 1991 (Abstract # 1167).
40. Opal SM, Fisher CJ, Cross AS, Marra MN, Scott RW, Palardy JE. Bactericidal/permeability-increasing protein as an anti-endotoxin therapeutic agent. The 31st Annual Meeting ICAAC, Chicago, Illinois, September 29, 1991 (Abstract # 791).
41. Boyce JM, Dickerson R, Opal SM, Medeiros AA. Changing level of heterogenous resistance in Methicillin-resistant S. aureus isolated during burn unit outbreak. The 31st Annual Meeting, ICAAC, Chicago, Illinois, September 29, 1991 (Abstract # 495).

42. Fisher CJ, Slotman G, Opal S, Pribble J, Catellano M and the IL-1RA Study Group. Results of a Phase II Study of IL-1RA in The Treatment of Sepsis Syndrome. American College of Chest Physicians 57th Annual Meeting. San Francisco, California, November 7, 1991.
43. Wedel N, Parent B, Conlon P, Gazzano-Sentoro H, Opal S, Trown P. Preclinical and Clinical Properties of the Anti-LPS Monoclonal Antibody E5. International Symposium on The Recognition of Endotoxin Biological Systems (Abstract # 363) March 6, 1992.
44. Wedel N, Parent B, Opal SM, Romulo R.L.C., Palardy JE. Anti-endotoxin monoclonal antibody E5 decreases endotoxin levels and improves survival in neutropenic rat model of Pseudomonas sepsis. Shock Society Annual Meeting. Birmingham, Alabama. June 4, 1992 (Abstract # 116).
45. Bhattacharjee AK, Opal SM, Drabick JJ, Collins H, Cross AS. Both IgG and IgM fractions of serum from rabbits immunized with E. coli J5 protect neutropenic rats from lethal bacteremia. American Federation of Research, Baltimore, MD. May 6, 1992. (Abstract #382A).
46. Boyce JM, Potter-Bynoe G, Opal SM, Medeiros AA. Common source outbreak of MRSA associated with respiratory therapy and nursing personnel. Society of Hospital Epidemiologists of American Annual Meeting. Baltimore, MD. April 12, 1992.
47. Romulo RLC, Opal SM, Palardy JE. Anti-endotoxin monoclonal antibody E5 enhances survival in neutropenic rats when combined with empiric antimicrobial therapy in pseudomonas sepsis. American Society for Microbiology Annual Meeting. New Orleans, LA. May 17, 1992. (Abstract # E57).
48. Monti S, Opal SM, Palardy JE, Boyce JM. Nosocomial C. difficile diarrhea: risk factors, complications and costs. Society of Hospital Epidemiologists of America, Annual Meeting. Baltimore, MD. April 12, 1992.
49. Opal SM, Fisher CJ, Cross AS, Palardy JE, Hoover DL, Marra MN, Scott RW. BPI as an anti-endotoxin therapeutic agent. American Federation of Clinical Research Meeting. Baltimore, MD. May 5, 1992. (Abstract # 213A)
50. Lanore J, Dhainaut JR, Fisher CJ, Opal SM, Zimmerman J, Nightingale P, et al. Effects of an anti-TNF IgG monoclonal antibody on left ventricular performance in septic patients. 6th European Congress on Intensive Care Medicine. Barcelona, Spain, October 27, 1992 (Abstract # 41).

51. Dhainaut JF, Fisher CJ, Opal SM, et al. Anti-TNF IgG monoclonal antibody in sepsis syndrome: pharmacokinetics, safety and role of IL-6 as a predictor of survival. American Thoracic Association International Conference, Miami, Florida, May 17, 1992. (Abstract # A318).
52. Dhainaut JF, Fisher CJ, Opal SM, et al. Anti-TNF MAb in sepsis syndrome: safety immunogenicity and survival benefit. 6th European Congress on Intensive Care Medicine. Barcelona, Spain, October 17, 1992. (Abstract # 46).
53. Gordon G, Fisher CJ, Slotman G, Opal SM, Pribble J, Catalano M. Cost-effectiveness of interleukin 1-receptor antagonist in sepsis. American Federation of Clinical Research, Baltimore, MD. April 12, 1992. (Abstract # 254A)
54. Romulo RLC, Ramirez BL, Navarro X, Opal SM. Tumor necrosis factor levels in primary Dengue infection. 32nd Annual Meeting - Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, California, October 11-14, 1992. (Abstract #1661)
55. Opal SM, Fisher CJ, Slotman GJ, Bone RC, Emmanuel G, Pribble JP, Stiles DM, Catalano MA, Ng D, LaBrecque JF, and the IL-1 Sepsis Study Group. The Phase II Interleukin-1 Receptor Antagonist (IL-1ra) Syndrome Trial: Analysis of Clinical, Cytokine, and Microbial Features with Outcome. 32nd Annual Meeting - Interscience Conference on Antimicrobial Agents and Chemotherapy. Anaheim, California, October 11-14, 1992. (Abstract # 1570)
56. Dubin H, Durkin M, Opal SM. An "expert" computer system to improve critical care decision making and resident education. The 22nd Annual Meeting of the Society of Critical Care Medicine. Suppl. 21(4). New York, New York, June 9-13, 1993 (Abstract # S187).
57. Boyce, JM, Potter-Bynoe G, Opal SM, Medeiros AA. Nosocomial dissemination of plasmid-mediated, vancomycin-resistant Enterococcus faecium and its control by stringent infection control measures. American Society for Microbiology Annual Meeting. Atlanta, Georgia, May 13, 1993. (Abstract L-7)
58. Knaus W, Harrell F, Fisher J, Opal S, Hein M, Sadoff J. Evaluating new drugs for sepsis: a prospective study design based on survival analysis. American Federation of Clinical Research, Washington DC, May 1, 1993. (Abstract # 252A)
59. Bhattacharjee A, Cross AS, Opal SM, Palardy JE. Purified IgG fraction of J5 antisera is protective in neutropenic rat model. American Federation of Clinical Research. Washington, DC, April 30, 1993. (Abstract # 247A).

60. Knaus W, Harrell F, Fisher CJ, Opal SM, Hein M, Sadoff J. An individual risk assessment approach to design and analysis of clinical trials for patients with sepsis and organ failure. Pharmacoepidemiology Annual Meeting, August 1993. (Abstract A-433)
61. Opal SM. Assessment of BPI in animal models of sepsis. The Fourth Annual Vienna Shock Society Meeting. Vienna, Austria, May 8, 1993. (Abstract # 12.4)
62. Boyce JM, Opal SM, Medeiros AA. In vitro activity and efficacy of teicoplanin against outbreak strains of Enterococcus faecium with plasmid-mediated Van B-type resistance. 18th International Congress of Chemotherapy. Stockholm, Sweden. July 1, 1993 (Abstract # p-181-1257).
63. Cross AS, Sadoff J, Gemski P, Opal S. Selection of Bacteria for Animal Models of Sepsis. The Second Consensus Development Conference on the Treatment of Radiation Injuries. National Radiobiology Research Institute. Bethesda, Maryland. April 14, 1993. (Abstract # A-1).
64. Knaus W, Harrell F, Fisher CJ, Opal S, Sadoff J, Wagner D. An individual patients risk assessment approach to design and analysis of clinical trials for patients with sepsis and organ failure. 4th Annual Vienna Shock Forum. Vienna, Austria, May 10, 1993 (Abstract # 5.2).
65. Fisher CJ, Slotman G, Opal S, Dhainaut J-F, Pribble J. The human recombinant IL-1ra in the treatment of patients with sepsis syndrome. 4th Annual Vienna Shock Forum. Vienna, Austria, May 11, 1993 (Abstract # 11.8).
66. Opal SM, Palardy JE, Romulo RLC, Smith C. Interleukin-1 receptor antagonist in an actual infection model of Pseudomonas sepsis. Infectious Disease Society of America Annual Meeting. New Orleans, LA, 1993 (Abstract # 12)
67. Opal SM, Palardy JE, Romulo RLC, Cross AS, Rousfeau A-M. Tumor Necrosis Factor Receptor-FC Fusion Protein in the Treatment of Experimental Sepsis. 33rd Annual ICAAC, New Orleans, Louisiana. October 18, 1993 (Abstract # 1417)
68. Opal SM, Sadoff JC, Fisher CJ, Dhainaut J-F, Pribble JP, Stiles DM, Knaus WA. Initial Findings of the IL-1ra Phase III Trial in Patients with Severe Sepsis. 33rd Annual ICAAC, New Orleans, Louisiana. October 18, 1993 (Abstract # 20)
69. Horn DL, Hewlatt D, Alfalla C, Franchini D, Pella P, Peterson S, Opal M. Limited tolerance of ofloxacin and pyrazinamide prophylaxis following exposure to RISE resistant tuberculosis. 33rd Annual ICAAC, New Orleans, La. Oct 18, 1993 (Abstract # 609).

70. Boyce JM, Opal SM, Medeiros AA, Mermel L. The value of standard and molecular epidemiologic methods in an outbreak of methicillin-resistant *S. aureus* infection. The Annual Gordon Conference, Andover, New Hampshire, August 10, 1993.
71. Pribble J, Fisher C, Opal S, Balk R, Slotman G, Reines D, Shelley M, Dhainaut J-F, Stiles D, Knaus W, Sadoff J. Human recombinant IL-1ra increases survival time in patients with sepsis and end organ dysfunction. Society of Critical Care Medicine Annual Meeting. February 1994, Orlando, Florida (Abstract # R-0413)
72. Opal SM. Clinical Trials of Sepsis: What lessons have we learned. Sepsis Association of New England. Boston, Massachusetts, January 1994 (Abstract # 12).
73. Noe L, Pribble J, Barriere S, Fisher C, Dhainaut J-F, Opal S, Gordon G. The impact of interleukin-1 receptor antagonist on hospital and ICU length of stay in patients with sepsis syndrome. Society of Critical Care Medicine Annual Meeting, Orlando, Florida, February 1994. (Abstract # R-0409)
74. Opal SM, Fisher CJ, Dhainaut J-F, Bodmer M. Anti-tumor necrosis factor strategies -- The CB6 monoclonal antibody study. 3rd International Congress on the Immune Consequences of Trauma, Shock, and Sepsis. March, 1994, Munich, Germany. Intensive Care Medicine (Abstract # 751).
75. Opal SM, Cross AS, Sadoff J. Animal models of sepsis: Their value and limitations. 3rd International Congress on The Immune Consequences of Trauma, Shock, and Sepsis. March, 1994, Munich, Germany. Intensive Care Medicine (Abstract # 331).
76. Noe LL, Pribble JP, Levy H, Opal SM, Bolle R, Fisher CJ, Dhainaut JR, Bloom BS, Barriere SL, Gordon GS. A comparison of hospital resource efficiency in patients with sepsis treated with Anakinra. 7th European Congress on Intensive Care Medicine. Innsbruck, Austria, March 31, 1994.
77. Marra MN, Scott RW, McKelligan BM, Opal SM. Bactericidal/ permeability-increasing protein levels exceed lipopolysaccharide binding protein in fluids at infected sites. American Federation of Clinical Research, Baltimore, Maryland, April 29, 1994, Clinical Research Abstract 152A.
78. Pribble JP, Fisher CJ, Opal SM, Balk RA, Slotman GJ, Shelly MP, Dhainaut JP and the IL-1ra sepsis study group. Recombinant human IL-1ra increases survival time in patients with sepsis as a function of disease severity. 7th European Congress on Intensive Care Medicine. Innsbruck, Austria, March 31, 1994.

79. Orange JS, Wolf SF, Miller AH, Spencer RL, McEwen BS, Opal SM, Biron CA. Mechanisms for IL-12-mediated effects on resistance to viral infection: Low dose protective immune response and high dose immunotoxicity associated with TNF and steroid induction. Cytokine Symposium, Philadelphia 1994 (Abstract # 14).
80. Orange JS, Salazar-Mather T, Opal SM, Biron CA. TNF expression and function during protective immune response to viral infection. Federation of the American Society of Experimental Biology Annual Meeting Journal. 1994 8(5) (Abstract #5755).
81. Fisher CJ, Pribble J, Opal SM, Dhainaut J-F, Stiles D. Interleukin-1-receptor antagonist improves survival time in sepsis and multiorgan failure. 3rd International Congress on the Immune Consequences of Trauma, Shock and Sepsis. March 1994, Munich, Germany. Intensive Care Medicine (Abstract # 755).
82. Noe L, Pribble J, Barriere S, Drummond M, van Hout B, Bloom B, Levy H, Opal S, Balk R, Johnson S, Dhainaut J, Gordon G. An analysis of hospital length of stay in a double-blind, placebo-controlled clinical trial of recombinant human IL1-ra in the treatment of patients with sepsis. European Symposium on Pharmacoeconomics. Gent, Belgium, May 18, 1994 (Abstract # 003).
83. Opal SM, Palardy J, Marra M, Scott R, McKelligon B, Romulo RLC, Activity of LBP-BPI fusion peptide in experimental gram negative sepsis. 34th Interscience Conference of Antimicrobial Agents and Chemotherapy. Orlando, Florida, October 7, 1994 (Abstract #B55).
84. Saniel M, Carlos C, White M, Opal SM. Field based epidemiology and molecular analysis of a multidrug resistant outbreak of typhoid fever in Metro Manila, Philippines. 4th Western Pacific Congress on Chemotherapy and Infectious Diseases. Bangkok, Thailand, December 1994 (Abstract #328).
85. Pribble JP, Fisher CJ, Opal SM, Balk R, Slotman G, Reines D, Shelly M, Dhainaut J-P, Stiles D, Sadoff J. Recombinant human interleukin-1 receptor antagonist increases survival time in patients with sepsis-induced organ dysfunction. American College of Chest Physicians Annual Meeting. New Orleans, LA, November, 1994. (Abstract #55)
86. Saniel M, Donskey C, Opal S, Mermel L, Palardy J, Giorgio C, Dayrit M, Carlos C, Mendoza M. The clinical and molecular epidemiology of an outbreak of multi-drug resistant typhoid fever in Metro Manila. Infectious Disease Society of America Annual Meeting. Orlando, FL, October 6, 1994 (Abstract #365).
87. Agosti JM, Fisher CJ, Opal SM, Lowry SF, Balk RA, Sadoff JC, and the sTNFR Sepsis Study Group. Treatment of patients with sepsis syndrome with soluble TNF receptor (sTNFR). 34th Annual ICAAC. October 5, 1994, Orlando, FL (Abstract # M4).

88. Orange JS, Salazar-Mather JP, Opal SM, Spencer RL, Miller HH, McEwen BS, Biron CA. Role of TNF in IL-12 induced toxicities during viral infection. Keystone Symposium on Molecular Aspects of Viral Immunity. Keystone, Colorado, January 1995 (Abstract J2-113).
89. Brathwaite C, Slotman G, Friedman B, Pribble J, Shelly M, Sadoff J, Opal SM, Balk R, Dhainaut JF, Fisher CJ, Thompson R. The effect of IL-1ra on organ dysfunction and survival in post operative surgical patients with sepsis syndrome. 5th Vienna Shock Forum, Vienna, Austria, May 11, 1995 Shock, Abstract # 3:204.
90. Opal SM, Cross AS, Sadoff J, Fisher CJ. Combination immunotherapy in sepsis. 5th Vienna Shock Forum, Vienna, Austria, May 11, 1995, Shock, Abstract #3:211.
91. Opal SM: Endotoxin as a measure of prognosis and clinical responsiveness in sepsis. Breakfast Club Symposium. The 15th Annual International Symposium of Intensive Care and Emergency Medicine (Abstract 1-A), March 22, 1995.
92. Opal SM, Palardy JE, Parejo N, Dubin P, Fisher CJ, Vincent JL. Endotoxemia in Sepsis. Therapeutic and prognostic implications. 35th Annual ICAAC Meeting. San Francisco, CA. September 21, 1995 (Abstract # G88).
93. Opal SM, Palardy JE, Donsky C, Jhung J, Cross AS. Potential hazards of combination immunotherapy in septic shock. 35th Annual ICAAC Meeting, San Francisco, CA. September 21, 1995 (Abstract #B36).
94. Opal SM. Clinical trials for sepsis, have we given up? 35th Annual ICAAC Meeting, San Francisco, CA. September 21, 1995. (Abstract # E-1).
95. Barna B, Fisher C, Starkey C, Jacobs B, Opal SM. Evaluation of endotoxin levels in sepsis: comparative analysis of chromogenic vs. turbidimetric methods. 4th IBC Conference on Endotoxemia and Sepsis. Philadelphia, PA, June 15, 1995 (Abstract # 12)
96. Opal SM. Lessons learned in clinical trials of sepsis; where did they go wrong? IBC Conference on Endotoxemia and Sepsis, Philadelphia, PA. June 15, 1995. (Plenary Session)
97. Opal SM. The relevance of animal models in the development of new therapeutic agents in sepsis. NIH Conference on the Future of Sepsis Research, Bethesda, MD, August 3-4, 1995.

98. Bhattacharjee AK, Opal SM, Taylor R, Naso R, Semenuk M, Zollinger WD, Moran E.E. Sadoff JC, Cross AS. Antibodies raised in rabbits against De-O-acylated E. coli J5 LPS protect neutropenic rats against gram-negative bacteria. IBC Conference on Endotoxemia and sepsis. June 19-21, Philadelphia, PA. (Abstract # 4)
99. Opal SM. The clinical relevance of antibiotic-induced endotoxin release. Society of Critical Care Medicine (New Jersey Chapter) Annual Meeting, Philadelphia, PA, October 1, 1995 (Abst # 5).
100. Opal SM, Keith JC, Jr., Schaub RG, Palardy J, Parejo N, Jhung J, Bhattacharjee A, Young L. Beneficial effects of recombinant human interleukin-11(rhIL-11) in an experimental model of gram-negative sepsis in neutropenic animals. American Society of Hematology Annual Meeting, Seattle, WA, December 1, 1995 (Abst. # 1980).
101. Cross AS, Bhattacharjee AK, Opal SM, Young L, Buffum K, Zollinger W. Active immunization of animals with an anti- endotoxin vaccine (dJS LPS/omp) elicits protective levels of antibody during cyclophosphamide-induced neutropenia. The 2nd International Symposium on Febrile Neutropenia. Brussels, Belgium, December 14, 1995 (Abstract #6896).
102. Opal SM, Palardy JE, Parejo N, Horn DL. The In vivo relevance of differential antibiotic-induced endotoxin release in experimental sepsis. Symposium and Workshop on Antibiotic Induced Endotoxin Release. Morristown, New Jersey, January 17-18, 1996.
103. Tilbert N, Blazek J, Mikolich D, Opal SM, Silverblatt F, Tack M, . The role of electronic thermometers in the transmission of vancomycin-resistant enterococci. Association of Practitioners of Infection Control Annual Meeting. Atlanta, Georgia, June 2, 1996.
104. Opal SM, Palardy JE, Parejo N, Horn DL. In vivo significance of antibiotic-induced endotoxin release in experimental gram-negative sepsis. 96th Annual Meeting of the American Society for Microbiology. New Orleans, LA, May 20, 1996 (Abstract A-9)
105. Opal SM, Horn DL. Clinical relevance of endotoxin release by antibiotics in the treatment of gram-negative infections. International Congress of Infectious Diseases. Hong Kong, June 12, 1996 (Abstract # 48.02).
106. Opal SM, Cross AS, Bhattacharjee A, Palardy JE, Parejo NA, Young LD. Active immunization with an E. coli J5 LPS vaccine in an experimental model of gram-negative sepsis. 36th Annual ICAAC Meeting, New Orleans, LA. September 17, 1996 (Abstract #G-1).

107. Ruzek MC, Miller AH, Opal SM, Pearce BD, Biron CA. Characterization of IL-6-dependent glucocorticoid induction during viral infection. 6th Annual Meeting of Neuroimmunomodulation, New York, New York, December 1996.
108. Opal SM. Interleukin-11: novel inhibition of inflammatory mediators. Annual Meeting, International Society of Experimental Hematology. New York, NY. August 23, 1996 (Abstract # 6).
109. Opal SM. The microbiological consequences of anti-mediator therapy in the treatment of sepsis. Toronto Symposium on Outcome Measures in Sepsis Trials. (Abstract # 32) Toronto, Canada, October 4-6, 1996.
110. Opal SM, The impact of antibiotic-induced endotoxin release in clinical medicine. The 4th International Symposium of the Immune Consequences of Shock, Trauma, and Sepsis. Munich, Germany, March 6, 1997 (in press).
111. Opal SM, Keith JC, Jr. Interleukin-11 as a potential agent to prevent progression of physiologic insults into multiple organ dysfunction syndrome. The 4th International Symposium of the Immune Consequences of Shock, Trauma, and Sepsis. Munich, Germany, March 6, 1997 (in press).
112. Opal SM. Gram-positive and gram-negative infections. Clinical similarities and differences. The 4th International Symposium of the Immune Consequences of Shock, Trauma, and Sepsis. Munich, Germany, March 8th, 1997 (in press).
113. Opal SM. Reconstituted high density lipoprotein as a treatment strategy for septic shock. The 7th Annual IBC Meeting on Endotoxemia and Sepsis, Washington, DC. April 28, 1997 (in press).
114. Orange, JS, Salazar-Mather TP, Opal SM, Biron CA. TNF-mediated liver damage during murine cytomegalovirus infection. The 4th International Symposium of the Immune Consequences of Shock, Trauma and Sepsis. Munich, Germany, March 5, 1997 (in press).
115. Mikolich DJ, Tilbert RN, Blazek-D'Arezzo J, Silverblatt FJ, Opal SM, Rounds S. Contamination of respiratory therapy equipment with vancomycin-resistant enterococci. 24th Annual Association of Professionals in Infection Control Meeting. Chicago, Illinois, May 12, 1997 (in press).

CVOPAL:21JAN97

THIS PAGE BLANK (USPTO)